| __timestamp | Bausch Health Companies Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 1271353000 |
| Thursday, January 1, 2015 | 582800000 | 1620577000 |
| Friday, January 1, 2016 | 455000000 | 2052295000 |
| Sunday, January 1, 2017 | 366000000 | 2075142000 |
| Monday, January 1, 2018 | 414000000 | 2186100000 |
| Tuesday, January 1, 2019 | 471000000 | 3036600000 |
| Wednesday, January 1, 2020 | 452000000 | 2735000000 |
| Friday, January 1, 2021 | 465000000 | 2908100000 |
| Saturday, January 1, 2022 | 529000000 | 3592500000 |
| Sunday, January 1, 2023 | 604000000 | 4439000000 |
| Monday, January 1, 2024 | 5132000000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, innovation is key. Over the past decade, Regeneron Pharmaceuticals, Inc. and Bausch Health Companies Inc. have shown contrasting approaches to research and development (R&D) investments. From 2014 to 2023, Regeneron consistently outpaced Bausch Health, investing nearly 5 times more in R&D by 2023. This commitment to innovation is evident as Regeneron's R&D expenses grew from approximately $1.27 billion in 2014 to $4.44 billion in 2023, marking a staggering 250% increase. In contrast, Bausch Health's R&D spending increased by about 145%, from $246 million to $604 million over the same period. This disparity highlights Regeneron's aggressive strategy to lead in pharmaceutical advancements, while Bausch Health maintains a more conservative approach. As the industry evolves, these investment trends could significantly impact each company's future market position and innovation capabilities.
R&D Insights: How Merck & Co., Inc. and Regeneron Pharmaceuticals, Inc. Allocate Funds
Research and Development Expenses Breakdown: Merck & Co., Inc. vs Bausch Health Companies Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Summit Therapeutics Inc.
Regeneron Pharmaceuticals, Inc. or TG Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and ImmunityBio, Inc.
Regeneron Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. Allocate Funds
Research and Development Investment: Jazz Pharmaceuticals plc vs Bausch Health Companies Inc.
Research and Development Expenses Breakdown: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Bausch Health Companies Inc. vs Wave Life Sciences Ltd.: Strategic Focus on R&D Spending
R&D Insights: How Bausch Health Companies Inc. and Taro Pharmaceutical Industries Ltd. Allocate Funds